Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$105,000.00
Biosensors for Bedside Detection of Urinary Biomarkers
EF 2015-16
Résumé
Medical tests commonly use urine to identify the levels of a myriad of biomolecules, but this requires the samples being sent to a lab. Thus there exists room for detection of important biomarkers (indicators of disease) at the bedside. This project will create biosensors capable of rapid equipment-free detection of a variety biomarkers indicative of ailments ranging from infection to cancer.
One such ailment is urinary tract infections (UTIs), up to 80% of which are caused by E.coli. My predecessors have coupled E.coli detectors with a molecule capable of producing a visible colour change to create an equipment-free biological sensor (biosensor). I will employ this biosensor in urine in order to learn how to combat the issues that arise, and determine optimal parameters, before attempting the more complex endeavour of detecting of cancer-specific biomarkers in urine.
Although this E.coli-specific biosensor has never been tested in urine, it can detect presence of cells at levels above what is typically considered a UTI in water. Thus, its successful implementation in urine could make it a feasible alternative to the existing lengthy and complex methods involving personnel and machinery, such as the current standards which involve culturing and a 24-48 hour wait.
After successfully addressing the problems that arise in urine-based tests, through optimization of the E.coli biosensor, I will focus on biomarkers that recent studies have shown to be indicative of cancers of the bladder or prostate.
Studies suggest matrix metalloproteinase 2 (MMP-2) to be the most suitable candidate, due to large differences in its urinary levels in healthy patients compared to cancer patients. I will derive a detector for this protein using a method pioneered by my supervisor, and couple it with our molecule capable of producing a visible colour change to create a biosensor. Thereby enabling rapid and equipment-free detection of this cancer indicator in urine samples, at the bedside.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
347965
Name
Manochehry Sepehr
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Biosensors for Bedside Detection of Urinary Biomarkers
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Biosensors; Cancer Diagnostics; Functional Nucleic Acids; Point-Of-Care Diagnostics; Urinary Biomarkers
Abstract
Medical tests commonly use urine to identify the levels of a myriad of biomolecules, but this requires the samples being sent to a lab. Thus there exists room for detection of important biomarkers (indicators of disease) at the bedside. This project will create biosensors capable of rapid equipment-free detection of a variety biomarkers indicative of ailments ranging from infection to cancer.
One such ailment is urinary tract infections (UTIs), up to 80% of which are caused by E.coli. My predecessors have coupled E.coli detectors with a molecule capable of producing a visible colour change to create an equipment-free biological sensor (biosensor). I will employ this biosensor in urine in order to learn how to combat the issues that arise, and determine optimal parameters, before attempting the more complex endeavour of detecting of cancer-specific biomarkers in urine.
Although this E.coli-specific biosensor has never been tested in urine, it can detect presence of cells at levels above what is typically considered a UTI in water. Thus, its successful implementation in urine could make it a feasible alternative to the existing lengthy and complex methods involving personnel and machinery, such as the current standards which involve culturing and a 24-48 hour wait.
After successfully addressing the problems that arise in urine-based tests, through optimization of the E.coli biosensor, I will focus on biomarkers that recent studies have shown to be indicative of cancers of the bladder or prostate.
Studies suggest matrix metalloproteinase 2 (MMP-2) to be the most suitable candidate, due to large differences in its urinary levels in healthy patients compared to cancer patients. I will derive a detector for this protein using a method pioneered by my supervisor, and couple it with our molecule capable of producing a visible colour change to create a biosensor. Thereby enabling rapid and equipment-free detection of this cancer indicator in urine samples, at the bedside.
Competitiondate
201510
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Manochehry, Sepehr
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~